Protecting Cerebrovascular Function— From Translational Science to Clinical Trials

 
 
 

Moderators:

 

Robert O Bonow
Elliott Antman
Robert Harrington

Panelists:

 

Jeffrey Weitz
John M Murkin
Mark Clay

Presentation:

Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Analysis from the ROCKET AF Trial  

Jonathan P Piccini, Duke Clinical Res Inst, Duke Univ Medical Ctr, Durham, NC

 

Discussion Q&A  

 

Presentation:

Cerebrovascular Autoregulation Impairment is Associated with Elevations in Plasma Glial Fibrillary Acidic Protein During Congenital Heart Surgery  

Ronald B Easley, Baylor Coll of Med, Houston, TX

 

Discussion Q&A